AzurRx BioPharma, Inc.
AZRX · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $11,851 | $53,688 | $23,323 | $18,682 |
| - Cash | $163 | $6 | $176 | $1,114 |
| + Debt | $141 | $0 | $1,605 | $255 |
| Enterprise Value | $11,828 | $53,682 | $24,751 | $17,822 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$15,621 | -$26,831 | -$13,724 | -$12,633 |
| % Margin | – | – | – | – |
| Net Income | -$18,059 | -$32,671 | -$15,178 | -$13,534 |
| % Margin | – | – | – | – |
| EPS Diluted | -5.33 | -5.903 | -6.77 | -8.77 |
| % Growth | 9.7% | 12.8% | 22.8% | – |
| Operating Cash Flow | -$9,218 | -$11,222 | -$14,034 | -$10,869 |
| Capital Expenditures | $0 | -$4 | -$24 | -$55 |
| Free Cash Flow | -$9,218 | -$11,226 | -$14,058 | -$10,925 |